Abstract

Lung transplantation is a recognised treatment for patients with end stage pulmonary disease. Transplant recipients receive life-long administration of immunosuppressive drugs that target T cell mediated graft rejection. However little is known of the impact on NK cells, which have the potential to be alloreactive in response to HLA-mismatched ligands on the lung allograft and in doing so, may impact negatively on allograft survival. NK cells from 20 healthy controls were assessed in response to Cyclosporine A, Mycophenolic acid (MPA; active form of Mycophenolate mofetil) and Prednisolone at a range of concentrations. The impact of these clinically used immunosuppressive drugs on cytotoxicity (measured by CD107a expression), IFN-γ production and CFSE proliferation was assessed in response to various stimuli including MHC class-I negative cell lines, IL-2/IL-12 cytokines and PMA/Ionomycin. Treatment with MPA and Prednisolone revealed significantly reduced CD107a expression in response to cell line stimulation. In comparison, addition of MPA and Cyclosporine A displayed reduced CD107a expression and IFN-γ production following PMA/Ionomycin stimulation. Diminished proliferation was observed in response to treatment with each drug. Additional functional inhibitors (LY294002, PD98059, Rottlerin, Rapamycin) were used to elucidate intracellular pathways of NK cell activation in response to stimulation with K562 or PMA-I. CD107a expression was significantly decreased with the addition of PD98059 following K562 stimulation. Similarly, CD107a expression significantly decreased following PMA-I stimulation with the addition of LY294002, PD98059 and Rottlerin. Ten lung transplant patients, not receiving immunosuppressive drugs pre-transplant, were assessed for longitudinal changes post-transplant in relation to the administration of immunosuppressive drugs. Individual patient dynamics revealed different longitudinal patterns of NK cell function post-transplantation. These results provide mechanistic insights into pathways of NK cell activation and show commonly administered transplant immunosuppression agents and clinical rejection/infection events have differential effects on NK cell function that may impact the immune response following lung transplantation.

Highlights

  • Lung transplantation is an established treatment for patients with end stage pulmonary disease

  • In a cohort of healthy controls and lung transplant recipients (LTR) we performed a detailed analysis of NK cell function in the presence of differing stimulation conditions and following administration of the commonly used clinical immunosuppressants, calcineurin inhibitors, anti-proliferative agents and corticosteroids

  • We demonstrated using well-defined in vitro assays that the addition of specific immunosuppressive drugs differentially impacted on NK cell cytotoxicity, cytokine production and proliferation, which was dependent on the primary stimulus

Read more

Summary

Introduction

Lung transplantation is an established treatment for patients with end stage pulmonary disease. Whilst lung transplant recipients (LTR) require life-long administration of immunosuppressive drugs to minimize alloreactivity and maintain optimal lung allograft function, episodes of acute cellular rejection remain relatively common and complications of chronic rejection and decline in lung function continue to impact on long term survival. Human studies suggest that other effector cells of the immune system, such as NK cells, may have alloreactive potential and influence clinical outcomes following transplantation [1]. Whilst the intrinsic role of NK cells relates to host defence, more recent attention has focused on their role in influencing adverse clinical outcomes following allogeneic transplantation in the setting of either hematopoietic stem cells or solid organs [2,3,4,5,6]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.